This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ChimeriVax-West Nile
Description: The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstructural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses.
Deal Structure: Acambis is developing the ChimeriVax-West Nile vaccine using its proprietary ChimeriVax technology, which was originally developed in collaboration with St. Louis University.
In November 2007, Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that it has signed a global collaboration agreement with Acambis for the development and marketing of ChimeriVax-West Nile. Under the terms of the agreement, Acambis will continue to perform development activities, up to and including the filing of a license application in the U.S. Acambis will receive an upfront payment of $10 million and would be eligible for pre- and post-marketing milestone payments of up to $70 million.
In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was closed in September 2008.
ChimeriVax-West Nile News
Additional information available to subscribers only: